Clinical Trials Browser

Cholangiocarcinoma

Ovarian Neoplasms

Squamous Cell Carcinoma of Head and Neck

Colonic Neoplasms

Advanced Gastric Cancer

Stomach Neoplasms

Advanced Gastric Cancer

Biliary Tract Neoplasms

Mouth Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Nasopharyngeal Neoplasms

Uterine Cervical Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Nasopharyngeal Carcinoma

Small Cell Lung Carcinoma

Advanced Triple-Negative Breast Cancer

Stomach Neoplasms

Uterine Cervical Neoplasms

Osteosarcoma, Drug-Related Side Effects and Adverse Reactions

Triple Negative Breast Neoplasms

Thyroid Neoplasms

Recurrence, Gestational Trophoblastic Disease

Biliary Tract Neoplasms, Cholangiocarcinoma

Esophageal Squamous Cell Carcinoma

Breast Neoplasms

Esophageal Neoplasms

Chondrosarcoma, Drug-Related Side Effects and Adverse Reactions

Cholangiocarcinoma

Small Cell Lung Carcinoma

Stomach Neoplasms

Breast Neoplasms

Osteosarcoma

Colorectal Neoplasms

Recurrence, Lymphoma, Large B-Cell, Diffuse

Quality of Life

Efficacy and Safety

Neoplasm Metastasis, Osteosarcoma

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Stomach Neoplasms

Clinical Trials

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

SPARE-02

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Poetry-1

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Chemotherapy Combined With Apatinib and PD-1 Antibody

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Apatinib for the Elderly Advanced Gastric Cancer

First-line Chemotherapy for Recurrent Cervical Cancer

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

LANCET

Study of Apatinib in Patients With Differentiated Thyroid Cancer

GTN

ACABC

Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

AIAC

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

MK 01

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

APFAO

Apatinib in Refractory Colorectal Cancer

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

ARCAP

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer